Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Amortizatization of Intangibles (2021 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Amortizatization of Intangibles for 5 consecutive years, with $742000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Amortizatization of Intangibles fell 83.44% to $742000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $4.0 million, a 26.19% decrease, with the full-year FY2024 number at $7.2 million, up 477.33% from a year prior.
  • Amortizatization of Intangibles was $742000.0 for Q3 2025 at 4D Molecular Therapeutics, up from $722000.0 in the prior quarter.
  • In the past five years, Amortizatization of Intangibles ranged from a high of $4.5 million in Q3 2024 to a low of -$365000.0 in Q2 2021.
  • A 5-year average of $753722.2 and a median of $402000.0 in 2023 define the central range for Amortizatization of Intangibles.
  • Peak YoY movement for Amortizatization of Intangibles: soared 1581.82% in 2024, then crashed 83.44% in 2025.
  • 4D Molecular Therapeutics' Amortizatization of Intangibles stood at $1.5 million in 2021, then tumbled by 75.02% to $374000.0 in 2022, then tumbled by 70.59% to $110000.0 in 2023, then skyrocketed by 1581.82% to $1.8 million in 2024, then plummeted by 59.89% to $742000.0 in 2025.
  • Per Business Quant, the three most recent readings for FDMT's Amortizatization of Intangibles are $742000.0 (Q3 2025), $722000.0 (Q2 2025), and $703000.0 (Q1 2025).